Tempus Enters into Collaboration with Boehringer Ingelheim to Advance Cancer Treatment
Thursday, May 15, 2025
Tempus AI has entered into a new multi-year collaboration with Boehringer Ingelheim.
The partnership aims to support the development of Boehringer Ingelheim’s cancer research pipeline, building on previous work between the two companies.
Cancer continues to pose a significant global health challenge, despite progress in treatment and diagnosis. Boehringer Ingelheim remains committed to developing new therapies for patients with difficult-to-treat cancers.
Through this agreement, the company will gain access to Tempus’ de-identified dataset, which includes molecular, clinical, and imaging information. Boehringer will also use Tempus’ AI-enabled platform, Lens, to support drug development efforts.
The collaboration will focus on using data from patient cohorts to identify potential biomarkers, group patients more effectively, generate ideas for drug combinations, and discover new therapeutic targets. Additionally, it will help to improve understanding of patients’ journeys through the healthcare system.
By combining Tempus’ real-world patient data with Boehringer’s internal research, the two companies aim to speed up cancer drug discovery and development.
The partnership reflects a shared goal of using AI and data-driven methods to deliver new treatments to patients more efficiently.
Source: businesswire.com
